Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.55 USD
Change Today -0.02 / -3.51%
Volume 83.2K
BGMD On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

bg medicine inc (BGMD) Snapshot

Open
$0.56
Previous Close
$0.57
Day High
$0.59
Day Low
$0.51
52 Week High
01/30/15 - $1.22
52 Week Low
12/15/14 - $0.27
Market Cap
19.1M
Average Volume 10 Days
144.2K
EPS TTM
$-0.20
Shares Outstanding
34.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BG MEDICINE INC (BGMD)

bg medicine inc (BGMD) Related Businessweek News

No Related Businessweek News Found

bg medicine inc (BGMD) Details

BG Medicine, Inc., a commercial stage company, engages in developing and commercializing diagnostic products used to guide the patients suffering from heart failure and related disorders. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

7 Employees
Last Reported Date: 03/31/15
Founded in 2000

bg medicine inc (BGMD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $400.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $290.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $275.0K
Compensation as of Fiscal Year 2014.

bg medicine inc (BGMD) Key Developments

BGMD Seeks Acquisitions

BG Medicine, Inc. (NasdaqCM:BGMD) is seeking acquisitions. BGMD has filed a shelf registration in the amount of $75 million. BGMD intends to use net proceeds from sale of securities for working capital, intellectual property protection, enforcement and in-licensing, capital expenditures, investments, acquisitions and collaborations.

BG Medicine, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Financial Guidance for 2015

BG Medicine, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported product revenues of $437,000 compared to $739,000 a year ago. Loss from operations was $1,256,000 compared to $1,947,000 a year ago. Net loss was $1,348,000 or $0.04 per basic and diluted share compared to $2,179,000 or $0.08 per basic and diluted share a year ago. Net cash flows used in operating activities were $1,391,000 compared to $2,379,000 a year ago. The decline in total revenues principally reflected a decrease from the prior year quarter in product revenues generated from the sale of manual micro-titer plate platform BGM Galectin-3 Test. In light of the following developments, the company expected to reverse the sequential decline in revenues that the company have experienced over the last three quarters: Orders from large clinical laboratory customer appear to have stabilized; the company experiencing modest revenue growth from sales to the majority of clinical laboratory customers; Although sales related to independent research studies are difficult to predict, the company is currently experiencing modest revenue growth from this segment, and; the company expected recognizing incremental revenues from the U.S. market introduction of automated galectin-3 testing in the latter half of 2015. For the full year 2015, the company continued to expect to decrease operating cash burn as compared to 2014.

BG Medicine, Inc. to Report Q1, 2015 Results on May 14, 2015

BG Medicine, Inc. announced that they will report Q1, 2015 results at 8:30 AM, US Eastern Standard Time on May 14, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BGMD:US $0.55 USD -0.02

BGMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $53.97 USD +0.23
Bio-Reference Laboratories Inc $41.73 USD +0.47
BioMerieux €96.11 EUR -0.16
Laboratory Corp of America Holdings $120.75 USD -1.44
Quest Diagnostics Inc $71.83 USD -1.07
View Industry Companies
 

Industry Analysis

BGMD

Industry Average

Valuation BGMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BG MEDICINE INC, please visit www.bg-medicine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.